<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04063345</url>
  </required_header>
  <id_info>
    <org_study_id>SAHZJU CT015</org_study_id>
    <nct_id>NCT04063345</nct_id>
  </id_info>
  <brief_title>Long-term Clinical Outcomes of intraVascular Ultrasound-guided vs Angiography-guided Primary pErcutaneous Intervention in Patients With Acute ST Segment Elevated Myocardial Infarction</brief_title>
  <acronym>LOVEinSTEMI</acronym>
  <official_title>A Prospective, Open Label, Multicenter and Randomized Study of Clinical Outcomes of Intravascular Ultrasound -Guided and Angiography-Guided Primary Percutaneous Intervention in Patients With Acute ST Segment Elevated Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Affiliated Hospital, School of Medicine, Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ningbo No. 1 Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Second Affiliated Hospital, School of Medicine, Zhejiang University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To examine the impact of IVUS guidance on clinical outcomes in the patient with Acute ST
      Segment Elevated Myocardial Infarction.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Intravascular ultrasound (IVUS) has been increasingly used as a guide for percutaneous
      coronary intervention (PCI) during elective as well as emergent clinical scenario. Recent
      small number randomized studies, large scale registries as well as meta-analysis have
      consistently demonstrated advantages of IVUS-guidance over angiography-guide alone with
      respect to the lower incident of death, myocardial infarction and target vessel
      revascularization.

      There are sparse data available on the clinical impact of IVUS-guided PCI in the setting of
      acute myocardial infarction (AMI) and its use remains a matter of controversy as shown by
      previous studies. This study is to examine the impact of IVUS guidance on clinical outcomes
      in the patient with Acute ST Segment Elevated Myocardial Infarction (STEMI).
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2019</start_date>
  <completion_date type="Anticipated">October 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major adverse cardiac event (MACE) rate</measure>
    <time_frame>1 year</time_frame>
    <description>Defined as cardiac death, myocardial infarction (MI, Q-wave and non-Q-wave) and target vessel revascularization (TVR)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MACE rate</measure>
    <time_frame>2-3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target lesion revascularization (TLR) rate</measure>
    <time_frame>2-3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target lesion failure (TLF) rate</measure>
    <time_frame>2-3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TVR rate</measure>
    <time_frame>2-3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel failure (TVF) rate</measure>
    <time_frame>2-3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MI (Q-wave and non-Q-wave) rat</measure>
    <time_frame>2-3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac death rate</measure>
    <time_frame>2-3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-cardiac death rate</measure>
    <time_frame>2-3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All death (cardiac and non-cardiovascular) rate</measure>
    <time_frame>2-3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent Thrombosis (ST) rate (ARC definite/probable)</measure>
    <time_frame>2-3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>ST Elevation Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>IVUS-guided PCI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Percutaneous intervention under IVUS-guidance</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Angiography-guided PCI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Percutaneous intervention under angiograhy-guidance only</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>IVUS-guided PCI</intervention_name>
    <description>Performing intravascular ultrasound before or/and after percutaneous intervention</description>
    <arm_group_label>IVUS-guided PCI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Angiography-guided PCI</intervention_name>
    <description>Performing percutaneous intervention without intravascular ultrasound guidance</description>
    <arm_group_label>Angiography-guided PCI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical inclusion criteria:

               1. Age &gt; 18 years

               2. Onset of STEMI &gt; 30 minutes, but &lt; 12 hours

               3. ST segment elevation in at least 2 contiguous leads of≥ 1mm or newly developed
                  LBBB on ECG

               4. Willing and able to provide informed consent

          -  Angiographic inclusion criteria:

               1. Having at least one infarct-related coronary artery, of which (1) the Culprit
                  lesion is suitable for stenting (2) the reference diameter of culprit vessel is ≥
                  2.5 mm but ≤ 4 mm (3) the TIMI flow is ≤ 1 in culprit lesion segment prior to
                  guide wire crossing

               2. No excessive tortuosity and calcification in the culprit lesion segment that
                  allowing stent implantation

        Exclusion Criteria:

          -  Clinical exclusion criteria:

               1. Contraindicating to any concomitant study medications

               2. Having cardiogenic shock with hemodynamic instability

               3. A history of bleeding diathesis or known coagulopathy

               4. A history of cerebrovascular accident (CVA) or transient ischemic attack (TIA)
                  within the past 6 months; or a history of intracranial tumor, aneurysm or
                  arteriovenous malformations; or a history of active peptic ulcer or active
                  gastrointestinal (GI) bleeding within the past 2 months; or planned major
                  procedure within 6 weeks; or known platelet count &lt; 100,000 /mm3 or Hb &lt; 10 g/dL

               5. Planned surgery which may cause discontinuation of ADP-receptor antagonist

               6. Other serious illness (e.g., cancer) that may reduce life expectancy to less than
                  1 year

               7. Repeated MI within 7 days of hospitalization for acute MI

          -  Anigographic Exclusion Criteria:

               1. Bifurcated lesion unable to identify the culprit lesion

               2. The culprit lesion is located in the left main artery

               3. Diffusive lesions without distinguishable culprit lesion

               4. Previous stent implantation in the culprit lesion segment or STEMI caused by
                  stent thrombosis

               5. Likely CABG procedure within 30 days

               6. Renal failure requiring or during dialysis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jian-an Wang, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Second Affiliated Hospital of Zhejiang University, School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jun Jiang, MD, PhD</last_name>
    <phone>+86-13588706891</phone>
    <email>drjayj@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Liang Dong, MD, PhD</last_name>
    <phone>+86-13858188861</phone>
    <email>chenhaibo1030@zju.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Second affiliated Hospital Zhejiang University School of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310009</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jun Jiang, MD, PhD</last_name>
      <phone>+86-13588706891</phone>
      <email>drjayj@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 19, 2019</study_first_submitted>
  <study_first_submitted_qc>August 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 21, 2019</study_first_posted>
  <last_update_submitted>August 20, 2019</last_update_submitted>
  <last_update_submitted_qc>August 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>STEMI</keyword>
  <keyword>Intravascular ultrasound</keyword>
  <keyword>Angiography</keyword>
  <keyword>Primary percutaneous intervention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

